Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can we deliver randomized trials of focal therapy in prostate cancer?
Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M; Prostate Cancer RCT Consensus Group. Ahmed HU, et al. Among authors: heer r. Nat Rev Clin Oncol. 2014 Aug;11(8):482-91. doi: 10.1038/nrclinonc.2014.44. Epub 2014 Apr 22. Nat Rev Clin Oncol. 2014. PMID: 24751803 Review.
A core outcome set for localised prostate cancer effectiveness trials.
MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N, Lam T; COMPACTERS Study Group. MacLennan S, et al. BJU Int. 2017 Nov;120(5B):E64-E79. doi: 10.1111/bju.13854. Epub 2017 May 3. BJU Int. 2017. PMID: 28346770 Free article.
Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer?
Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M; and the Prostate Cancer RCT Consensus Group. Ahmed HU, et al. Among authors: heer r. Nat Rev Clin Oncol. 2017 Sep 12. doi: 10.1038/nrclinonc.2017.86. Online ahead of print. Nat Rev Clin Oncol. 2017. PMID: 28895571
The co-chaperone p23 promotes prostate cancer motility and metastasis.
Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL. Cano LQ, et al. Among authors: heer r. Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6. Mol Oncol. 2015. PMID: 25241147 Free PMC article.
Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.
Clark E, Morton M, Sharma S, Fisher H, Howel D, Walker J, Wood R, Hancock H, Maier R, Marshall J, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R. Clark E, et al. Among authors: heer r. BMJ Open. 2019 Dec 18;9(12):e034708. doi: 10.1136/bmjopen-2019-034708. BMJ Open. 2019. PMID: 31857319 Free PMC article.
121 results